ABSTRAK

Kombinasi regimen paklitaksel-cisplatin merupakan salah satu regimen yang

digunakan di RSUP Sanglah Denpasar. Kombinasi regimen paklitaksel-cisplatin
merupakan first line kemoterapi untuk kanker serviks. Penelitian ini dilakukan untuk
mengetahui perbedaan massa tumor, nilai BUN, dan serum kreatinin sebelum dan
sesudah 6 seri kemoterapi dengan paklitaksel-cisplatin pada pasien kanker serviks sel
skuamosa stadium IIB-IIIB. Penelitian yang dilakukan merupakan penelitian yang
bersifat observasional dengan menggunakan metode cohort prospektif. Follow-up
pada pasien dilakukan mulai dari kemoterapi seri I hingga kemoterapi seri VI. Data
dianalisis dengan uji t berpasangan atau dengan uji Wilcoxon.
Sebanyak lima pasien yang memenuhi kriteria inklusi dan eksklusi dievaluasi
massa tumornya, nilai BUN, dan serum kreatinin selama 6 seri kemoterapi. Secara
klinis, terjadi penurunan ukuran massa tumor sebelum kemoterapi I dan setelah
kemoterapi VI, meskipun secara statistic nilai penurunan tersebut berbeda tidak
bermakna (p>0.05). Rerata nilai serum kreatinin dan BUN sebelum kemoterapi I dan
sesudah kemoterapi paklitaksel cisplatin seri VI masih berada dalam rentang normal.
Secara statistik, nilai serum kreatinin dan BUN sebelum kemoterapi I dan sesudah
kemoterapi paklitaksel cisplatin seri VI berbeda tidak bermakna (p>0.05).
Tidak terdapat perbedaan yang bermakna pada massa tumor, BUN, dan serum
kreatinin sebelum kemoterapi I dan sesudah kemoterapi VI paklitaksel cisplatin pada
pasien kanker serviks sel skuamosa stadium IIB-IIIB.

Kata Kunci: kanker serviks, paklitaksel-cisplatin, massa tumor, serum kreatinin, BUN

ABSTRACT
The combination of paclitaxel-cisplatin regimen is one of the chemotherapy
regimen used in Sanglah Hospital Denpasar. The combination of paclitaxel-cisplatin
regimen is the first line chemotherapy for cervical cancer. This study was conducted
to perceive the changes in tumor mass, BUN value and creatinine serum before and
after 6 series of chemotherapy with paclitaxel-cisplatin in patients with stages IIBIIIB squamous cell cervical cancer. The research is conducted as an observational
study using a prospective cohort study method. follow-up on patients is conducted
from the first to the last series of chemotherapy. The data were analyzed with paired t
test or the Wilcoxon test.
A total of five patients fitting the inclusion and exclusion criteria were evaluated
of their tumor mass, BUN value and creatinine serum during six series of
chemotherapy. Clinically, decreasing of the tumor mass prior to the first series of
chemotherapy and after the last series of chemotherapy can be observed, although
statistically the decrease in value was not significant (p> 0.05). The mean value of
creatinine serum and BUN value before the first and after the last paclitaxel-cisplatin
chemotherapy series are still within the normal range. Statistically, the BUN value
and creatinine serum before the first and after the last paclitaxel-cisplatin
chemotherapy series were not significantly different (p> 0.05).
There were no significant changes in tumor mass, BUN value and creatinine
serum before the first and after the last paclitaxel-cisplatin chemotherapy series in
patients with stages IIB-IIIB squamous cell cervical cancer.

Keywords: cervical cancer, paclitaxel-cisplatin, tumor-mass, creatinine serum, BUN